Browsing by Author "Hirayama, R"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    P219 / #908 - advancements in NCEPT: animal study outcomes and technological developments toward clinical application
    (Elsevier, 2024-06) Hirayama, R; Tashima, H; Hamato, A; Howell, NR; Sierro, F; Kielly, M; Caracciolo, A; Franklin, DR; Guatelli, S; Yamaya, T; Rosenfeld, AB; Fiorini, C; Carminati, M; Safavi-Naeini, M
    Background and aims: Neutron Capture Enhanced Particle Therapy (NCEPT) represents a promising advancement in cancer treatment, utilising neutron capture agents (NCAs) to enhance therapeutic efficacy of proton/heavy ion radiation. This work focuses on animal experiments and concurrent technological developments aimed at translating NCEPT into clinical practice. Methods: Animal studies were conducted to assess the therapeutic impact of NCEPT. Baseline dose response of U87MG xenograft Balb/c nu/nu mice to 12C and 4He ion radiation was evaluated at HIMAC (February 2021, January 2022). NCEPT dose-response experiments with 10B-BPA as the NCA and using the same animal model were conducted in two campaigns in 2023. 200 mice were irradiated with helium or carbon ions across four dose levels (0 Gy, 5 Gy, 10 Gy, and 15 Gy, n = 6 mice/ion/dose); tumour growth was measured at different time points. In parallel, a scintillator-based detector for measurement of photon spectrum changes due to neutron capture was developed and evaluated in simulations and experiments with boron-loaded PMMA targets irradiated by helium/carbon ion beams. Results: Baseline experiments showed expected dose-response relationships, with tumour response and measured neutron fluence informing the NCEPT study protocol. NCEPT experiments demonstrated significant tumour volume reductions (33%/46% for helium/carbon ion irradiation, respectively) and delays in tumour growth relative to baseline. The prototype detector measured increases in the area of the 478 keV peak by 26%/45% for helium/carbon beams, respectively, compared to simulation-based values of 57%/45%. >65% of these photons originated from 10B captures in the detector's PCB, highlighting the need for neutron shielding and boron-free materials in detector construction. The linear increase in neutron capture photons at 10B concentrations up to 20000 ppm, with potential for detection down to 100 ppm using temporal windowing, paves the way for a SPECT-like neutron capture imaging system, crucial for NCEPT quality assurance. Conclusion: The combined animal study outcomes and technological advancements underscore the potential of NCEPT as a highly effective cancer therapy. The progress in dosimetry and imaging techniques mark significant steps toward the clinical translation of NCEPT, promising improved patient outcomes in cancer treatment. © 2024 Elsevier B.V. Open Access under a CC-BY-NC-ND 4.0 licence